Subject: Genetics | Research Article | RC254-282 | VASCULAR-TARGETING AGENT, ENDOTHELIAL-CELLS, A4 PHOSPHATE, A-4 PHOSPHATE, KAPPA-B, SIGNAL-TRANSDUCTION, ANGIOGENESIS, CANCER, TRIAL, FACTOR-1-ALPHA | Cancer Research | Oncology | Neoplasms. Tumors. Oncology. Including cancer and carcinogens
<p>Abstract</p> <p>Background</p> <p>A functional vascular network is essential for the survival, growth and spread of solid tumours, making blood vessels a key target for therapeutic strategies. Combretastatin A-4 phosphate (CA-4-P) is a tubulin-depolymerising agent in... View more
Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM: Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003, 21(15):2823-30.
Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21(15):2831-42.
Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21(15):2815-22.
Young SL, Chaplin DJ: Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drugs 2004, 13:1171-1182.
Pettit GR, Rhodes MR: Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998, 13(3):183-91.
Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to 1.
8. tumour vascular targeting activity in vivo. Anticancer Res 2001, 21(1A):93-102.
9. Kanthou C, Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002, 99(6):2060-9.